University of Birmingham's cancer immunotherapy developer Revitope Oncology secured equity funding as part of a $160m alliance with Junshi Biosciences.
Revitope Oncology, a US-based cancer therapeutics spinout of University of Birmingham, is set to receive $10m in equity funding from biopharmaceutical firm Junshi Biosciences as part of a collaboration and licensing agreement.
Junshi could supply as much as $160m for each molecule discovered under the partnership in milestones and royalties. The equity funding is in exchange for a total 9.99% stake in Revitope, dependent on mutual agreement and applicable laws.
Revitope is developing a class of cancer immunotherapies…
